NCCN, Envision Pharma Group Partner to Streamline Clinical Trial Proposals
The National Cancer Comprehensive Network (NCCN) has selected Envision’s medical affairs platform to help manage proposals and investigator-initiated clinical trials in an effort to improve patient quality of life and reduce cancer-related deaths.
The NCCN Oncology Research Program (ORP) is designed to support research through collaborations with pharmaceutical companies and investigators from prominent cancer centers. Envision Technology Solutions’ web-based software platform (iEnvision) supports multiple medical affairs-related programs of activity, including investigator-led studies.
"In 2017 alone, the NCCN Oncology Research Program awarded funding to 11 new research projects and facilitated the publication of 13 abstracts and 13 manuscripts, all focused on improving treatment for people with cancer," said Susan Most, RN, MBA, director of clinical operations, NCCN ORP, in a statement to Journal of Clinical Pathways. "Switching to the iEnvision web-based platform enables us to provide a more efficient, user-friendly experience for investigators and research personnel. This allows more time for the important work they do improving patients' lives, which ultimately affects patient outcomes."
After NCCN launches their iEnvision-based solution and migrates active studies into the system, they estimate 50 proposal submissions and 70 active studies will be managed annually. NCCN will have the ability to communicate directly from within the system to the pharmaceutical companies who provide the research grants.
"We are pleased to have been able to provide the adaptation of our industry standard study management iEnvision module for NCCN, supporting their industry-wide coordination of important, independent oncology research,” said Kelli Walker, director of platform strategy, Envision, in a press release (February 26, 2018).
The web-based platform is expected to facilitate a consistent and cohesive experience for grant applicants, NCCN staff, and peer reviewers, which will ultimately lead to a more effective study selection process and improve patient quality of life as well as reduce cancer-related deaths.—Zachary Bessette